Skip to Content
Morningstar

Teva Pharmaceutical Industries Ltd TEVA

Morningstar Rating
Unlock
Stock XTAE Rating as of
—
View Full Chart
As of Delayed Price
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
TEVA is trading at a 700% premium.
Price
₪61.96
Fair Value
₪94.33
Uncertainty
High
1-Star Price
₪95.11
5-Star Price
₪22.14
Economic Moat
Sbd
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TEVA is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
—
Day Range
—–—
52-Week Range
—–—
Bid/Ask
— / —
Market Cap
—
Volume/Avg
— / —

Key Statistics

Price/Earnings (Normalized)
6.25
Price/Sales
1.16
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Large Value
Total Number of Employees
37,851
Website
https://www.tevapharm.com

Competitors

Valuation

View More
Metric
TEVA
VTRS
RDY
Price/Earnings (Normalized)
 6.254.2721.46
Price/Book Value
 2.490.724.04
Price/Sales
 1.160.954.02
Price/Cash Flow
 11.614.4117.69
Price/Earnings
TEVA
VTRS
RDY

Financial Strength

Metric
TEVA
VTRS
RDY
Quick Ratio
 0.470.661.84
Current Ratio
 0.891.672.58
Interest Coverage
 0.181.1541.67
Quick Ratio
TEVA
VTRS
RDY

Profitability

Metric
TEVA
VTRS
RDY
Return on Assets (Normalized)
 6.03%7.07%15.32%
Return on Equity (Normalized)
 35.36%16.57%21.28%
Return on Invested Capital (Normalized)
 12.54%9.85%19.75%
Return on Assets
TEVA
VTRS
RDY
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
VpvvjsvtdXxr$82.1 Bil
 Merck KGaA ADR
MKKGY
VwbgbvzvsCqzdy$75.2 Bil
 Haleon PLC ADR
HLN
YtfzmlrqXzjb$41.4 Bil
 Viatris Inc
VTRS
VcmgfrpvnDphrf$14.4 Bil
 Dr Reddy's Laboratories Ltd ADR
RDY
JyyhkgzmMhg$13.7 Bil
 Catalent Inc
CTLT
GjrnvlwbGgvmr$10.6 Bil
 Perrigo Co PLC
PRGO
WywvmjqwRfjf$3.8 Bil
 Prestige Consumer Healthcare Inc
PBH
JgnvczvjJhrrvbl$3.5 Bil
 Curaleaf Holdings Inc
CURLF
CpvktsybfKzmv$3.0 Bil
 Green Thumb Industries Inc
GTBIF
FnhbbrhksJzbm$2.7 Bil

Sponsor Center